What do systematic reviews say?

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

It is very uncertain whether inhaled tobramycin (TNS) (28 days) changes frequency of infective pulmonary exacerbations: number of… compared with TNS (56 days) (very low certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  OR 0.19 [0.01, 4]
  1 study · 77 participants
  Very low

Cycled inhaled tobramycin vs culture‐based TNS

Cycled inhaled tobramycin (TNS) probably leads to lower frequency of infective pulmonary exacerbations: proportion of… compared with culture‐based TNS (moderate certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  OR 0.75
  1 study · 304 participants
  Moderate

Ciprofloxacin vs placebo added to cycled and culture‐based inhaled tobramycin (TNS) therapy

Ciprofloxacin showed no clear difference in frequency of infective pulmonary exacerbations: proportion of… compared with placebo added to cycled and culture‐based inhaled tobramycin (TNS)… (moderate certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  OR 1.49 [0.95, 2.33]
  1 study · 304 participants
  Moderate

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 58 participants
  Very low

Oral ciprofloxacin and inhaled colistin vs inhaled tobramycin (TNS) plus oral ciprofloxacin

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with TNS plus oral placebo (moderate certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 0.75 [0.56, 1]
  1 study · 221 participants
  Moderate

Inhaled tobramycin (TNS) vs placebo

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral ciprofloxacin and inhaled colistin vs no treatment

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

The review found no eligible studies for this question.

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intravenous ceftazidime with tobramycin vs ciprofloxacin

Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).

• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 0.78 [0.55, 1.1]
  1 study · 285 participants
  High

Nebulised hypertonic saline vs nebulised 0.9% saline

• Nebulised hypertonic saline solution for acute bronchiolitis in infants 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 205 participants
  Very low

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs OD

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs other breathing techniques

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs exercise

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Summary of findings: ACBT vs CCPT

Summary of findings: ACBT showed no clear difference in number of pulmonary exacerbations compared with CCPT (low certainty).

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 1.64 [0.62, 4.34]
  1 study · 63 participants
  Low

PUFA vs placebo

• Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents 2023 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 869 participants
  High

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found